Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.70 |
| ▸ | FTO | Q9C0B1 | 8/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.43 |
| ▸ | KDM3A | Q9Y4C1 | 3/20 | 0.43 |
| ▸ | HIF1AN | Q9NWT6 | 2/20 | 0.42 |
| ▸ | KDM6B | O15054 | 2/20 | 0.40 |
| ▸ | VEGFA | P15692 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396850 | 0.82 | EGLN3 (1.00) | EGLN3FTOEGLN1KDM5BKDM2A | |
| SCHEMBL3398026 | 0.82 | EGLN3 (0.51) | EGLN3FTOEGLN2EGLN1KDM5B | |
| SCHEMBL3397991 | 0.81 | EGLN3 (0.44) | EGLN3 | |
| SCHEMBL3522309 | 0.80 | EGLN3 (0.57) | EGLN3FTOEGLN2EGLN1KDM5B | |
| SCHEMBL3394717 | 0.77 | EGLN1 (0.69) | EGLN3FTOEGLN2EGLN1KDM5B | |
| SCHEMBL3396187 | 0.77 | EGLN3 (0.76) | EGLN3FTOEGLN1VEGFAFLT1 | |
| SCHEMBL3397983 | 0.77 | EGLN3 (0.76) | EGLN3FTOEGLN1VEGFAFLT1 | |
| SCHEMBL3516662 | 0.74 | EGLN3 (0.57) | EGLN3FTOEGLN2EGLN1KDM5B | |
| SCHEMBL29045546 | 0.74 | EGLN1 (0.63) | EGLN3FTOEGLN2EGLN1VEGFA | |
| SCHEMBL3521101 | 0.72 | EGLN3 (0.54) | EGLN3FTOEGLN2EGLN1KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101932324-A | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC | 2010-12-29 | — | — | CN | claimed |
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | claimed |
| EP-2224926-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-08 | — | — | EP | claimed |
| WO-2009070644-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | claimed |
| CN-101932324-A | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC | 2010-12-29 | — | — | CN | disclosed |
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | disclosed |
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | disclosed |
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | disclosed |
| EP-2224926-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009070644-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070644-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885FTO 828/4885EGLN2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.